First human tests begin for new liver disease drug
NCT ID NCT07331545
Summary
This is the first human study of a new drug called QL2401, which is being developed for a serious liver condition called MASH. The study will test the safety and how the drug moves through the body in 70 healthy Chinese adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and how the body processes the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.